Poster un message

Topical cidofovir will be absorbed systemically and be associated with renal toxicity (914). Injectable therapy (e.g., interferon or 5-fluoracil/epinephringel implant) must be provided in solely severe recalcitrant circumstances due to inconvenient routes of administration, frequent office visits, and a high frequency of systemic adverse results. Systemic interferon-alfa therapy or intralesional cidofovir has been used as an investigational treatment with limited success in children, with frequent recurrences or extension into the trachea, bronchi, or lung parenchyma (CIII). Monitoring (...)